Literature DB >> 28589435

Epigenetic regulation of RTK signaling.

Jennifer M Spangle1,2, Thomas M Roberts3,4,5.   

Abstract

Receptor tyrosine kinase (RTK) signaling cascades coordinate intracellular signaling in response to growth factors, chemokines, and other extracellular stimuli to control fundamental biological processes such as cellular proliferation, metabolism, and survival. Hyperactivation of pathways associated with growth factor signaling (e.g., RTK and downstream effectors including Ras, PI3K/AKT, and Raf) is a frequent event in human cancers, which uncouples ligand-mediated activation with signal transduction. While the contributions of direct genomic events are well understood as causative agents of hyperactive signal transduction, other non-heritable genomic modifications promote the activation of growth factor-associated signaling cascades. In this review, we highlight epigenomic mechanisms by which hyperactivation of RTK-associated signaling cascades occurs and may contribute to cancer.

Entities:  

Keywords:  Cancer; Epigenetics; Receptor tyrosine kinases; Signal transduction

Mesh:

Substances:

Year:  2017        PMID: 28589435      PMCID: PMC5663182          DOI: 10.1007/s00109-017-1546-0

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  54 in total

Review 1.  Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection.

Authors:  Bingnan Zhang; Richard S Finn
Journal:  Liver Cancer       Date:  2016-05-10       Impact factor: 11.740

Review 2.  New and emerging HDAC inhibitors for cancer treatment.

Authors:  Alison C West; Ricky W Johnstone
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

Review 3.  Cell signaling by receptor tyrosine kinases.

Authors:  Mark A Lemmon; Joseph Schlessinger
Journal:  Cell       Date:  2010-06-25       Impact factor: 41.582

4.  S-adenosylmethionine inhibits the growth of cancer cells by reversing the hypomethylation status of c-myc and H-ras in human gastric cancer and colon cancer.

Authors:  Jin Luo; Yan-Ni Li; Fei Wang; Wei-Ming Zhang; Xin Geng
Journal:  Int J Biol Sci       Date:  2010-12-06       Impact factor: 6.580

5.  Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells.

Authors:  Y L Ottaviano; J P Issa; F F Parl; H S Smith; S B Baylin; N E Davidson
Journal:  Cancer Res       Date:  1994-05-15       Impact factor: 12.701

6.  Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors.

Authors:  R G Lapidus; A T Ferguson; Y L Ottaviano; F F Parl; H S Smith; S A Weitzman; S B Baylin; J P Issa; N E Davidson
Journal:  Clin Cancer Res       Date:  1996-05       Impact factor: 12.531

7.  Reversible acetylation regulates vascular endothelial growth factor receptor-2 activity.

Authors:  Annalisa Zecchin; Lucia Pattarini; Maria Ines Gutierrez; Miguel Mano; Antonello Mai; Sergio Valente; Mike P Myers; Sergio Pantano; Mauro Giacca
Journal:  J Mol Cell Biol       Date:  2014-03-11       Impact factor: 6.216

8.  COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.

Authors:  Cory M Johannessen; Jesse S Boehm; So Young Kim; Sapana R Thomas; Leslie Wardwell; Laura A Johnson; Caroline M Emery; Nicolas Stransky; Alexandria P Cogdill; Jordi Barretina; Giordano Caponigro; Haley Hieronymus; Ryan R Murray; Kourosh Salehi-Ashtiani; David E Hill; Marc Vidal; Jean J Zhao; Xiaoping Yang; Ozan Alkan; Sungjoon Kim; Jennifer L Harris; Christopher J Wilson; Vic E Myer; Peter M Finan; David E Root; Thomas M Roberts; Todd Golub; Keith T Flaherty; Reinhard Dummer; Barbara L Weber; William R Sellers; Robert Schlegel; Jennifer A Wargo; William C Hahn; Levi A Garraway
Journal:  Nature       Date:  2010-11-24       Impact factor: 49.962

9.  Insulator dysfunction and oncogene activation in IDH mutant gliomas.

Authors:  William A Flavahan; Yotam Drier; Brian B Liau; Shawn M Gillespie; Andrew S Venteicher; Anat O Stemmer-Rachamimov; Mario L Suvà; Bradley E Bernstein
Journal:  Nature       Date:  2015-12-23       Impact factor: 49.962

10.  Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.

Authors:  Molly Gale; Joyce Sayegh; Jian Cao; Michael Norcia; Peter Gareiss; Denton Hoyer; Jane S Merkel; Qin Yan
Journal:  Oncotarget       Date:  2016-06-28
View more
  9 in total

1.  Next-gen cancer research.

Authors:  Gregg L Semenza
Journal:  J Mol Med (Berl)       Date:  2017-08       Impact factor: 4.599

2.  Therapeutic Targeting of Stromal-Tumor HGF-MET Signaling in an Organotypic Triple-Negative Breast Tumor Model.

Authors:  Sunil Singh; Astha Lamichhane; Pouria Rafsanjani Nejad; Jacob Heiss; Hannah Baumann; Ravindra Gudneppanavar; Nic D Leipzig; Michael Konopka; Gary D Luker; Hossein Tavana
Journal:  Mol Cancer Res       Date:  2022-07-06       Impact factor: 6.333

Review 3.  Targeting DNA Double-Strand Break Repair Pathways to Improve Radiotherapy Response.

Authors:  Mahmoud Toulany
Journal:  Genes (Basel)       Date:  2019-01-04       Impact factor: 4.096

4.  In Vitro and In Silico Evaluation of Anticancer Activity of New Indole-Based 1,3,4-Oxadiazoles as EGFR and COX-2 Inhibitors.

Authors:  Belgin Sever; Mehlika Dilek Altıntop; Ahmet Özdemir; Gülşen Akalın Çiftçi; Doha E Ellakwa; Hiroshi Tateishi; Mohamed O Radwan; Mahmoud A A Ibrahim; Masami Otsuka; Mikako Fujita; Halil I Ciftci; Taha F S Ali
Journal:  Molecules       Date:  2020-11-07       Impact factor: 4.411

Review 5.  Targeting PI3K/Akt signal transduction for cancer therapy.

Authors:  Yan He; Miao Miao Sun; Guo Geng Zhang; Jing Yang; Kui Sheng Chen; Wen Wen Xu; Bin Li
Journal:  Signal Transduct Target Ther       Date:  2021-12-16

6.  Epigenetic Inheritance From Normal Origin Cells Can Determine the Aggressive Biology of Tumor-Initiating Cells and Tumor Heterogeneity.

Authors:  Jiliang Feng; Dawei Zhao; Fudong Lv; Zhongyu Yuan
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 3.302

Review 7.  PTEN/PTENP1: 'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy.

Authors:  Nahal Haddadi; Yiguang Lin; Glena Travis; Ann M Simpson; Najah T Nassif; Eileen M McGowan
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

8.  Selective Inhibition of HDAC Class I Sensitizes Leukemia and Neuroblastoma Cells to Anticancer Drugs.

Authors:  Elmira Vagapova; Maxim Kozlov; Timofey Lebedev; Karina Ivanenko; Olga Leonova; Vladimir Popenko; Pavel Spirin; Sergey Kochetkov; Vladimir Prassolov
Journal:  Biomedicines       Date:  2021-12-06

Review 9.  Targeting Protein Kinases and Epigenetic Control as Combinatorial Therapy Options for Advanced Prostate Cancer Treatment.

Authors:  Soghra Bagheri; Mahdie Rahban; Fatemeh Bostanian; Fatemeh Esmaeilzadeh; Arash Bagherabadi; Samaneh Zolghadri; Agata Stanek
Journal:  Pharmaceutics       Date:  2022-02-25       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.